These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1103 related items for PubMed ID: 17031284

  • 1. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N, Damico L, Shams N, Lowman H, Kim R.
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [Abstract] [Full Text] [Related]

  • 2. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ziemssen F, Heiduschka P, Schraermeyer U, Tübingen Bevacizumab Study Group.
    Retina; 2007 Oct; 27(8):1154-6; author reply 1156-8. PubMed ID: 18040264
    [No Abstract] [Full Text] [Related]

  • 3. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 4. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
    Wykrota H, Gierek-Lapińska A, Trzciakowski K, Gajdzik-Gajdecka U.
    Klin Oczna; 2007 Dec; 109(10-12):402-9. PubMed ID: 18488382
    [Abstract] [Full Text] [Related]

  • 5. Safety of ranibizumab therapy in wet AMD and the role of vascular endothelial growth factors in physiological angiogenesis.
    Figurska M, Robaszkiewicz J, Wierzbowska J.
    Klin Oczna; 2010 Dec; 112(4-6):147-50. PubMed ID: 20825071
    [Abstract] [Full Text] [Related]

  • 6. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group.
    Ophthalmology; 2007 Feb; 114(2):246-52. PubMed ID: 17270674
    [Abstract] [Full Text] [Related]

  • 7. Ranibizumab for the treatment of neovascular AMD.
    Kaiser PK, Do DV.
    Int J Clin Pract; 2007 Mar; 61(3):501-9. PubMed ID: 17313620
    [Abstract] [Full Text] [Related]

  • 8. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
    Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N.
    Am J Ophthalmol; 2008 Feb; 145(2):239-248. PubMed ID: 18222192
    [Abstract] [Full Text] [Related]

  • 9. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N.
    Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
    [Abstract] [Full Text] [Related]

  • 10. Ranibizumab: Phase III clinical trial results.
    Rosenfeld PJ, Rich RM, Lalwani GA.
    Ophthalmol Clin North Am; 2006 Sep; 19(3):361-72. PubMed ID: 16935211
    [Abstract] [Full Text] [Related]

  • 11. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group.
    Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
    [Abstract] [Full Text] [Related]

  • 12. Opportunities and challenges in the development of combination therapy for the treatment of retinal diseases.
    Hohman TC.
    Retina; 2009 Jun; 29(6 Suppl):S51-3. PubMed ID: 19553804
    [Abstract] [Full Text] [Related]

  • 13. Antiangiogenic approaches to age-related macular degeneration today.
    Bressler NM.
    Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
    [Abstract] [Full Text] [Related]

  • 14. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM, Brown GC, Brown HC, Peet J.
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [Abstract] [Full Text] [Related]

  • 15. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration.
    Mantel I, Zografos L, Ambresin A.
    Ophthalmologica; 2008 Jun; 222(5):321-3. PubMed ID: 18617755
    [Abstract] [Full Text] [Related]

  • 16. Anti-VEGF agents for age-related macular degeneration.
    Ozkiris A.
    Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
    [Abstract] [Full Text] [Related]

  • 17. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
    Sadda SR, Stoller G, Boyer DS, Blodi BA, Shapiro H, Ianchulev T.
    Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261
    [Abstract] [Full Text] [Related]

  • 18. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
    Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Guiberteau B, Quentel G.
    Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
    [Abstract] [Full Text] [Related]

  • 19. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
    Michels S, Rosenfeld PJ.
    Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
    [Abstract] [Full Text] [Related]

  • 20. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials.
    Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prünte C, Schmidt-Erfurth U, Tano Y, Wolf S.
    Br J Ophthalmol; 2010 Jan; 94(1):2-13. PubMed ID: 19443462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.